Phase Ib study of sabatolimab (<scp>MBG453</scp>), a novel immunotherapy targeting <scp>TIM‐3</scp> antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes
Andrew M. Brunner, Jordi Esteve, Kimmo Porkka, Steven Knapper, Elie Traer, Sebastian Scholl, Guillermo Garcia‐Manero, Norbert Vey, Martin Wermke, Jeroen J. W. M. Janssen, Rupa Narayan, Shaun Fleming, Sun Loo, Natalia Tovar, Mika Kontro, Oliver G. Ottmann, Purushotham Naidu, Haiying Sun, May Han, Roisin White, Na Zhang, Anisa Mohammed, Catherine Sabatos-Peyton, David P. Steensma, Mikael L. Rinne, Uma Borate, Andrew H. Wei
Abstract
The safety and efficacy of sabatolimab, a novel immunotherapy targeting T-cell immunoglobulin domain and mucin domain-3 (TIM-3), was assessed in combination with hypomethylating agents (HMAs) in patients with HMA-naive revised International Prognostic System Score (IPSS-R) high- or very high-risk myelodysplastic syndromes (HR/vHR-MDS) or chronic myelomonocytic leukemia (CMML). Sabatolimab + HMA had a safety profile similar to that reported for HMA alone and demonstrated durable clinical responses in patients with HR/vHR-MDS. These results support the ongoing evaluation of sabatolimab-based combination therapy in MDS, CMML, and acute myeloid leukemia.